Status:

RECRUITING

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Lead Sponsor:

AstraZeneca

Conditions:

Biliary Tract Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection ...

Detailed Description

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter, global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigat...

Eligibility Criteria

Inclusion

  • Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma (CCA) or muscle invasive gallbladder cancer (GBC)) after macroscopically complete resection (R0 or R1)
  • Provision of a tumor sample collected at surgical resection.
  • Randomization within 12 weeks after resection with adequate healing and removal of drains.
  • Confirmed to be disease-free by imaging within 28 days prior to randomization.
  • Eastern Cooperative Oncology Group performance status of 0 or 1

Exclusion

  • Participants with locally-advanced, unresectable, or metastatic disease at initial diagnosis.
  • Ampullary cancer, neuroendocrine, mixed neuroendocrine and non-neuroendocrine neoplasms and nonepithelial tumors.
  • Any anti-cancer therapy for BTC prior to surgery
  • Active or prior documented autoimmune or inflammatory disorders or any severe or uncontrolled systemic disease
  • Current or prior use of immunosuppressive medication within 14 days before the first dose
  • Thromboembolic event within 3 months
  • Active HBV or HCV infection unless treated.

Key Trial Info

Start Date :

December 4 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 3 2030

Estimated Enrollment :

750 Patients enrolled

Trial Details

Trial ID

NCT06109779

Start Date

December 4 2023

End Date

May 3 2030

Last Update

November 26 2025

Active Locations (210)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 53 (210 locations)

1

Research Site

Birmingham, Alabama, United States, 35233

2

Research Site

Phoenix, Arizona, United States, 85054

3

Research Site

Duarte, California, United States, 91010

4

Research Site

Los Angeles, California, United States, 90089